Tech Company Financing Transactions
Exicure Funding Round
Exicure closed a $11.2 million funding round on 11/7/2017. Investors included Luye Pharma, Eager Info Investments and Knoll Capital Management.
Transaction Overview
Company Name
Announced On
11/7/2017
Transaction Type
Venture Equity
Amount
$11,200,000
Round
Undisclosed
Investors
Luye Pharma (Lead Investor) (Li Xin)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
8045 Lamon Ave. 410
Skokie, IL 60077
USA
Skokie, IL 60077
USA
Phone
Website
Email Address
Not Recorded
Overview
AuraSense Therapeutics is a development-stage biotechnology company founded to pursue the unique commercial potential of Spherical Nucleic Acid (SNA) constructs. These novel constructs possess unparalleled biocompatibility and versatility as therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Giljohann
Chief Financial Officer
David Snyder
Chief Operating Officer
Matthias Schroff
Browse more venture capital transactions:
Prev: 11/7/2017: ChartMogul venture capital transaction
Next: 11/7/2017: QLess venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs